We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under... Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Show more
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the companyβs management team will participate in fireside chats at the following...
="/Images/box-unchecked.jpg" alt="Checkbox not checked">150804/28/2023COMPENSATION* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.6545 | -2.74769101595 | 23.82 | 24.07 | 22.7 | 2074420 | 23.78049293 | CS |
4 | 1.0855 | 4.91621376812 | 22.08 | 24.07 | 21.87 | 2465459 | 22.89325833 | CS |
12 | -0.5745 | -2.4199663016 | 23.74 | 24.07 | 19.2 | 2376981 | 22.13862219 | CS |
26 | 0.9755 | 4.39612438035 | 22.19 | 24.34 | 18.64 | 2294241 | 21.88409625 | CS |
52 | 4.5855 | 24.6797631862 | 18.58 | 24.34 | 18.08 | 2365701 | 20.91083532 | CS |
156 | 0.6155 | 2.72949002217 | 22.55 | 25.77 | 14.87 | 2329793 | 19.58510142 | CS |
260 | -0.1345 | -0.577253218884 | 23.3 | 27.9 | 13.67 | 2473406 | 20.06968941 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions